US active pharmaceutical ingredients (API) manufacturer Cambrex Corporation has announced the expansion of large-scale manufacturing capacity at its cGMP plant in Karlskoga, Sweden. The investment will focus on additional continuous flow manufacturing for the production of high purity intermediates.

The expansion at the New Jersey-headquartered company’s Swedish site is part of an ongoing strategic campaign to invest in small molecule API manufacturing across its global network of facilities. Cambrex regards itself as the leading manufacturer of small molecule innovator and generic APIs.

The company said the project, which includes the installation of new multi-purpose reactors, including a 9m³ hydrogenation reactor, and upgrading of the control room within an existing plant on site, is due to be completed by Q3 2017. The Karlskoga facility supports clients’ development projects from R&D to large scale commercial manufacturing. Installation of all new equipment.

Along with increasing output capability, Cambrex has introduced a dedicated continuous flow production unit at Karlskoga, which it said is capable of producing multiple tonnage of of high purity intermediates annually.

“The additional capacity at the site, within our current infrastructure, will enable us to service our existing and future customers more efficiently,” said Bjarne Sandberg, managing director of Cambrex Karlskoga. The continuous flow unit builds on the company’s long experience with continuous flow and high energy chemistry and allows for greater production efficiency and flexibility, he added.